Last reviewed · How we verify
Active bupropion, No counseling
Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to improve mood and reduce cravings.
Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to improve mood and reduce cravings. Used for Major depressive disorder, Smoking cessation (nicotine dependence).
At a glance
| Generic name | Active bupropion, No counseling |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Target | Norepinephrine transporter (NET) and dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Bupropion blocks the reuptake of norepinephrine and dopamine at the neuronal synapse, leading to increased concentrations of these neurotransmitters in the central nervous system. This mechanism differs from selective serotonin reuptake inhibitors and is thought to enhance motivation, energy, and reward processing. The drug is used primarily for depression and smoking cessation.
Approved indications
- Major depressive disorder
- Smoking cessation (nicotine dependence)
Common side effects
- Insomnia
- Dry mouth
- Headache
- Nausea
- Dizziness
- Seizures
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active bupropion, No counseling CI brief — competitive landscape report
- Active bupropion, No counseling updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI